StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$127.16+2.49 (+2.00%)

Close on Nov 18, 2026Market cap $8.23BP/E 123.5Yield –

Protagonist Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Protagonist Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $58.34M, up 143.3% year over year. For fiscal 2025 it was -$158.13M, down 162.5% from the year before. The highest annual figure on record is $252.84M in fiscal 2024.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$158.13M-162.5%
FY2024Dec 31, 2024$252.84M–
FY2023Dec 31, 2023-$93.65M–
FY2022Dec 31, 2022-$131.37M–
FY2021Dec 31, 2021-$125.85M–
FY2020Dec 31, 2020-$64.52M–
FY2019Dec 31, 2019-$80.52M–
FY2018Dec 31, 2018-$42.27M–
FY2017Dec 31, 2017-$37.90M–
FY2016Dec 31, 2016-$32.67M–
FY2015Dec 31, 2015-$14.79M–
FY2014Dec 31, 2014-$9.32M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$158.77M–
Q1 FY2026Mar 31, 2026-$3.65M–
Q4 FY2025Dec 31, 2025-$50.36M-139.7%
Q3 FY2025Sep 30, 2025-$46.42M–
Q2 FY2025Jun 30, 2025-$42.04M–
Q1 FY2025Mar 31, 2025-$19.31M-109.4%
Q4 FY2024Dec 31, 2024$126.78M+450.0%
Q3 FY2024Sep 30, 2024-$41.45M–
Q2 FY2024Jun 30, 2024-$38.79M–
Q1 FY2024Mar 31, 2024$206.31M–
Q4 FY2023Dec 31, 2023$23.05M–
Q3 FY2023Sep 30, 2023-$38.33M–
Q2 FY2023Jun 30, 2023-$42.35M–
Q1 FY2023Mar 31, 2023-$36.02M–
Q4 FY2022Dec 31, 2022-$36.52M–
Q3 FY2022Sep 30, 2022-$32.30M–
Q2 FY2022Jun 30, 2022-$41.44M–
Q1 FY2022Mar 31, 2022-$21.11M–
Q4 FY2021Dec 31, 2021-$37.02M–
Q3 FY2021Sep 30, 2021-$33.93M–
Q2 FY2021Jun 30, 2021-$30.88M–
Q1 FY2021Mar 31, 2021-$24.02M–
Q4 FY2020Dec 31, 2020-$18.83M–
Q3 FY2020Sep 30, 2020-$7.77M–
Q2 FY2020Jun 30, 2020-$18.22M–
Q1 FY2020Mar 31, 2020-$19.70M–
Q4 FY2019Dec 31, 2019-$17.30M–
Q3 FY2019Sep 30, 2019-$17.17M–
Q2 FY2019Jun 30, 2019-$31.41M–
Q1 FY2019Mar 31, 2019-$14.65M–
Q4 FY2018Dec 31, 2018-$15.41M–
Q3 FY2018Sep 30, 2018-$9.39M–
Q2 FY2018Jun 30, 2018-$9.24M–
Q1 FY2018Mar 31, 2018-$8.23M–
Q4 FY2017Dec 31, 2017-$3.51M–
Q3 FY2017Sep 30, 2017-$4.98M–
Q2 FY2017Jun 30, 2017-$15.13M–
Q1 FY2017Mar 31, 2017-$14.27M–
Q4 FY2016Dec 31, 2016-$11.40M–
Q3 FY2016Sep 30, 2016-$7.14M–

More Protagonist Therapeutics figures

See a number that looks wrong?